A Phase 1/2a Study Utilizing 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) in Patients with Sarcoma or Gastrointestinal Tract Cancer (PHANTOM Trial)

This is a multicenter, open-label, prospective Phase 1/2a study to assess safety and tolerability, establish dosimetry and to identify an optimal imaging dose (radioactivity and mass dose) and imaging time window of 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) and to compare its imaging biodistribution with FAP expression by immunohistochemistry (IHC) in patients with sarcomas or GIT cancers. The study will be conducted in 2 parts (Part 1 and Part 2).

开始日期2024-11-01

申办/合作机构

Lantheus Medical Imaging, Inc.

NCT06361810 / Not yet recruiting临床1/2期IIT

A Phase 1/2 Open-label Study of Pembrolizumab Combined With PNT-2002 Radioligand Therapy in Patients With Metastatic Renal Cell Carcinoma

This is a multi-center, single arm open label phase 1b/2 study of pembrolizumab in combination with 177Lu-PNT2002 (also known as 177Lu-PSMA I&T) radiopharmaceutical therapy in patients with metastatic clear cell renal cell carcinoma (RCC) who have progressed after prior treatment with anti-programmed cell death protein 1 (PD1) or PD-L1 immune-checkpoint inhibitors (ICIs). The study comprises 2 phases: an open-label Phase 1b dose escalation portion followed by a Phase 2 dose expansion portion. Investigators hypothesize that pembrolizumab in combination with 177Lu-PNT2002 in in patients with metastatic clear cell RCC at a biologically active dose will result in tolerable safety profile and it will lead to improved radiological objective responses in patients who have progressed after prior treatment with standard anti-PD1 or anti- Programmed Cell Death Ligand 1 (PDL1) immune-checkpoint inhibitor containing regimen when compared to historic controls. Patients in both phases will have prostate-specific membrane antigen (PSMA), positron emission tomography (PET) imaging with the radiotracer (F-18)-DCFPyl, to help detect any spread of the cancer.

开始日期2024-11-01

申办/合作机构

Lantheus Medical Imaging, Inc.

[+1]

NCT05160480 / Enrolling by invitationN/AIIT

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).

开始日期2024-06-07

申办/合作机构

University of California, Davis

[+1]

100 项与 Lantheus Medical Imaging, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Lantheus Medical Imaging, Inc. 相关的专利（医药）

登录后查看更多信息

项与 Lantheus Medical Imaging, Inc. 相关的文献（医药）

2023-10-01·Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Pharmacological and metabolic parameters of [18F]flubrobenguane in clinical imaging populations

Article

作者: Mair, Braeden A ; Saint-Georges, Zacharie ; Dinelle, Katie ; deKemp, Robert A ; Zelt, Jason G E ; Adi, Myriam ; Robinson, Simon ; Nekesa, Kirabo ; Beanlands, Rob S ; Shlik, Jakov ; Mielniczuk, Lisa M ; Rotstein, Benjamin H

BACKGROUND:

Cardiac sympathetic nervous system molecular imaging has demonstrated prognostic value. Compared with meta-[¹¹C]hydroxyephedrine, [¹⁸F]flubrobenguane (FBBG) facilitates reliable estimation of SNS innervation using similar analytical methods and possesses a more convenient physical half-life. The aim of this study was to evaluate pharmacokinetic and metabolic properties of FBBG in target clinical cohorts.

METHODS:

Blood sampling was performed on 20 participants concurrent to FBBG PET imaging (healthy = NORM, non-ischemic cardiomyopathy = NICM, ischemic cardiomyopathy = ICM, post-traumatic stress disorder = PTSD). Image-derived blood time-activity curves were transformed to plasma input functions using cohort-specific corrections for plasma protein binding, plasma-to-whole blood distribution, and metabolism.

RESULTS:

The plasma-to-whole blood ratio was 0.78 ± 0.06 for NORM, 0.64 ± 0.06 for PTSD and 0.60 ± 0.14 for (N)ICM after 20 minutes. 22 ± 4% of FBBG was bound to plasma proteins. Metabolism of FBBG in (N)ICM was delayed, with a parent fraction of 0.71 ± 0.05 at 10 minutes post-injection compared to 0.53 ± 0.03 for PTSD/NORM. While there were variations in metabolic rate, metabolite-corrected plasma input functions were similar across all cohorts.

CONCLUSIONS:

Rapid plasma clearance of FBBG limits the impact of disease-specific corrections of the blood input function for tracer kinetic modeling.

2014-01-01·JACC. Cardiovascular imaging1区 · 医学

Acute Mortality in Critically Ill Patients Undergoing Echocardiography With or Without an Ultrasound Contrast Agent

1区 · 医学

Article

作者: Main, Michael L ; Miller, Paula ; Lowe, Timothy J ; Ryan, Amy ; Bhat, Gajanan ; Hibberd, Mark G

OBJECTIVES:

The objective of this observational study was to compare 48-h all-cause mortality (as well as hospital stay mortality) among critically ill patients who underwent echocardiography either with or without an ultrasound contrast agent (UCA).

BACKGROUND:

The safety of perflutren-based UCAs has been questioned by the U.S. Food and Drug Administration (particularly when administered to critically ill patients) following rare reports of deaths or life-threatening adverse reactions that occurred in close temporal relationship to UCA administration.

METHODS:

This was a retrospective observational outcome study conducted in critically ill patients to compare all-cause 48-h and hospital stay mortality subsequent to echocardiography procedures performed either with or without a UCA. The study utilized discharge data from a database maintained by Premier, Inc. (Charlotte, North Carolina). Premier's database is the largest U.S. hospital-based, service-level comparative database for quality and outcomes research, and provides detailed resource utilization data along with patients' primary and secondary diagnoses and procedure billing codes. A propensity score-matching algorithm between UCA-enhanced echocardiography patients and non-contrast-enhanced echocardiography patients was utilized to reduce the potential for imbalance in covariates of selected patients in the comparison of mortality between groups.

RESULTS:

Patients undergoing echocardiography with a UCA had lower mortality at 48 h compared with patients undergoing non-contrast-enhanced echocardiography (1.70% vs. 2.50%), with an odds ratio = 0.66 (95% confidence interval [CI]: 0.54 to 0.80). Patients undergoing echocardiography with a UCA had lower hospital stay mortality compared with patients undergoing noncontrast echocardiography (14.85% vs. 15.66%), with an odds ratio = 0.89 (95% CI: 0.84 to 0.96).

CONCLUSIONS:

In critically ill, propensity-matched hospitalized patients undergoing echocardiography, use of a UCA is associated with a 28% lower mortality at 48 h in comparison with patients undergoing non-contrast-enhanced echocardiography. These results are reassuring, given previous reports suggesting an association between UCAs and increased mortality in critically ill patients.

2013-04-01·Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography2区 · 医学

American Society of Echocardiography Cardiovascular Technology and Research Summit: A Roadmap for 2020

2区 · 医学

Article

作者: Tamer M. Mahmoud ; Nakela L. Cook ; Neil J. Weissman ; Theodore P. Abraham ; Sherif F. Nagueh ; Stefan Husson ; Steve Metz ; Michael H. Picard ; Pamela S. Douglas ; Maurice E. Sarano ; Sam Maslak ; Rudy Rodriguez ; Olaf T. Von Ramm ; Lissa Sugeng ; Peter Chen ; Anand Tatpati ; Hector Lopez ; Marti L. McCulloch ; Gunnar Hansen ; Albert Sinusas ; Thomas R. Porter ; Benjamin F. Byrd ; Alan S. Pearlman ; Marielle Scherrer-Crosbie ; Girish S. Shirali ; Shaun Zamani ; David Prater ; Julius M. Gardin ; Howard Leong-Poi ; Denis B. Buxton ; Philippe Pibarot ; Hélène C. Houle ; Patricia A. Pellikka ; Roberto M. Lang ; Allan L. Klein ; Sanjiv Kaul ; Flordeliza S. Villanueva ; Rolf Baumann ; Jack J. Slosky ; James G. Miller

项与 Lantheus Medical Imaging, Inc. 相关的新闻（医药）

2024-04-05

·BiG生物创新社

核药接住了泼天的富贵：过去5年的交易、投资、市场格局

作者｜文心第二代放射性药物在肿瘤学领域的商业成功重新点燃了人们对这种治疗模式的兴趣，引起该领域公司的交易激增，风险融资增加。鉴于这一新兴的行业兴趣，Brianne Sullivan等人在Nature发文“The radiopharmaceutical renaissance: radiating hope in cancer therapy”。据此，本文评估了过去5年放射性药物领域的交易和投资格局，涵盖了治疗、诊断和诊断加治疗药物。 01 一代核药历经曲折，二代核药终获成功！系统放射性药物作为癌症的治疗方法首次应用于20世纪40年代，当时医生使用放射性碘治疗甲状腺癌症。鉴于早期放射治疗缺乏效力，以及由于缺乏特异性而产生的副作用，后来的药物经过发展，由科学家通过将放射性同位素与靶向部分（如肿瘤特异性小分子、肽或抗体）连接起来，开发出了更安全、更有效的药物。商业上可用的抗体放射治疗药物的出现始于本世纪初，2002年和2003年分别批准了Zevalin（ibritumomab tiuxetan；现在由Acrotech Biopharma销售）和Bexxar（tositumomab and iodine-131 [I-131] tositumomab；由葛兰素史克公司开发）用于治疗非霍奇金淋巴瘤。尽管疗效显著，医生热情高涨，但几个关键挑战——包括生产和处理所需的专用设施、设备和专业知识——限制了它们的商业成功。Zevalin和Bexxar在上市后的十多年里销量一直很低，导致Zevalin的所有权多次变更，Bexxar被从市场上撤下。而第二代放射性药物Xofigo（radium-223 [Ra-223] dichloride；拜耳，2013年批准）、Luthathera（lutetium-177 [Lu-177] dotatate；Advanced Accelerator Applications，2018年批准）和Pluvicto（lutetium-177 [Lu-177] vipivotide tetraxetan；诺华，2022年批准）已在商业上取得成功。XofigoXofigo是唯一批准的α粒子靶向疗法，该药是一款可发射α粒子的放射活性治疗药物。来自关键III期ALSYMPCA研究的数据证实：在治疗伴症状性骨转移且无已知内脏转移的转移性去势抵抗性前列腺癌患者时，与安慰剂相比，Xofigo可提供三重获益：显著延长生存期、推迟首次症状性骨骼事件（SSE）的发生时间、改善生活质量。此外，Xofigo还具有良好的安全性。LuthatheraLuthathera是一种放射性配体疗法，该药物去年9月25日III期NETTER-2试验达到了主要终点。与单独使用大剂量长效奥曲肽相比，Lutathera联合长效奥曲肽一线治疗新诊断为体泌素受体阳性、2级和3级晚期胃肠胰神经内分泌肿瘤（GEP-NET）患者的无进展生存期（PFS）实现明显改善。PluvictoPluvicto被批准用于治疗转移性去势耐受性前列腺癌症，它已经步入了成为重磅药物的行列，据诺华公司报告，2023年，pluvicto销售额9.8亿美元，同比增长高达261%。与现有的治疗相比，疗效的提高，包括放射肿瘤学家在内的肿瘤学实践的发展，以及稳定性和安全性提高的放射性同位素的使用，都为该领域注入了活力。 02 “诊疗一体化”是核药发展的大趋势此外，放射性药物的使用范围逐渐从治疗领域扩展到诊断领域。含有放射性成分的诊断剂在特定器官、组织或细胞中积聚，能够检测异常或功能变化，长期以来一直用于评估肿瘤、神经系统疾病、炎症性疾病和感染。最近，诊断治疗放射性药物的开发得到了大力推动，这种药物结合了诊断和治疗特性，支持“发现即治疗”的方法。诊断成分用于可视化和评估疾病或病症，然后使用相同或互补的放射性药物用于治疗目的。以个性化方式将诊断和治疗相结合的能力，为改善患者预后、优化治疗策略和推进精准医学方法带来了巨大的希望。 03 过去5年，核药共交易86笔在过去5年里，放射性药物领域共进行了86笔战略交易，其中大多数是合作/共同开发（n=26）和基于授权（n=26）的协议。2018年至2021年，交易格局相对稳定。然而，在2022年，交易数量比2021年增加了近两倍（分别为n=25和n=9；图1a）。值得注意的是，在临床前阶段（n=20）达成的交易数量最多，主要是由具有现有核医学能力和专业知识的公司（如Fusion Pharmaceuticals和Novartis）推动的，这些公司寻求扩大其放射性药物管线。许多交易也发生在2期临床阶段（n=18）；主要涉及基于授权和收购的诊断放射性药物交易（图1a）。图注：2018-2023年放射性药物领域生物制药公司的交易分布。a，每年按阶段划分的交易数量。该领域的活跃整合者包括大型全球生物制药公司（如诺华和拜耳）和专门的核医学公司（如Fusion Pharmaceuticals和Curium Pharma），交易活动涉及诊断、治疗和治疗加治疗药物。诊断放射性药物在该领域的交易总数中占据相当大的比例（约41%），其次是诊断治疗药物（约32%）和治疗药物（约27%；图1b）。肿瘤学在诊断治疗药物交易领域占据主导地位（分别占交易的93%和100%）；诊断领域的大部分交易在神经学领域（54%），其次是肿瘤学（31%）。图注：2018-2023年放射性药物领域生物制药公司的交易分布。b，每种形式的按适应症划分的交易数量。数据来源：Cortellis。*截至2023年10月3日。在分析期间，有17笔交易在宣布时披露了财务条款（约20%）。在所有开发阶段和模式中，商业交易的平均潜在总价值为8.34亿美元（前期2.84亿美元，里程碑5.5亿美元）（图2a）。与诊断资产的平均总交易价值（3900万美元；n=4）相比，诊断治疗（n=4）和治疗（n=9）资产的潜在交易价值分别高达7.29亿美元和10.26亿美元。诊断治疗资产的平均前期交易价值是治疗资产的2倍，这可能是由于前者的临床和监管风险较低。图注：2018-2023年放射性药物领域生物制药公司的交易价值。a按方式分类的交易价值。在考虑资产到期时的交易价值时，随着技术在临床阶段的进展，临床阶段资产的价值不断增加，尽管与早期临床资产相比，发现阶段交易的总交易价值更高（图2b）。在发现阶段达成的交易中，大部分（97%）的价值在于里程碑付款，反映了这些基于合作的交易在放射性药物疗法的发现、开发和商业化方面的高风险、高回报性质。图注：2018-2023年放射性药物领域生物制药公司的交易价值。b，按阶段分类的交易价值。数据来源：Cortellis。*截至2023年10月3日。商业阶段的交易主要是并购——收购近期获得美国食品和药物管理局（FDA）批准的公司。值得注意的是，诺华公司在2018年支付了39亿美元的预付款，收购了Advanced Accelerator Applications公司，紧随其后的是FDA批准该公司的神经内分泌肿瘤（NET）诊断产品Netspot（镓[ga-68] dotatate试剂盒），几乎与FDA批准诺华的治疗性产品Lutathera的时间相吻合。 04 核药公司融资数量稳步增加，集中于肿瘤领域自2018年以来，放射性药物领域发生的融资数量（n=54）一直在稳步增加，主要集中在癌症适应症（n=45；图3）。最活跃的融资集中在诊断加治疗（50%），其次是治疗（34%）和诊断（16%），大多数融资发生在早期，分别为A系列（56%）和B系列（32%）。随着兴趣和临床开发的不断提高，融资水平也在不断提高；2023年前三季度，九次融资的平均融资额为5100万美元，约为2018年全年四次融资2600万美元的2倍（图3）。图注：2018-2023年放射性药物领域源自私募融资的风险投资。*融资从A轮到D轮。数据来源：Pitchbook。*截至2023年10月3日。 05 上市公司交易收购热情不减虽然围绕放射性药物的热情导致了交易的增加，但从2023年初开始在美国主要交易所（纽约证券交易所或纳斯达克）上市的五家放射性药物公司（Fusion Pharmaceuticals、Lantheus Medical Imaging、POINT Biopharma、Perspective Therapeutics和Actinium Pharmaceuticals）的表现喜忧参半。从年初到2023年10月3日，他们的表现从POINT Biopharma股价上涨71%到Actinium Pharmaceuticals股价下跌43%不等。五家公司中，位于中位数的公司Perspective Therapeutics的股价上涨了11%，远高于纳斯达克生物技术指数的增长幅度，该指数在同一时期内下跌了7%。公共放射性药物公司平均表现积极的一个可能原因是私人市场模式带来的兴奋情绪蔓延到了公共市场。支持这一理论的是RayzeBio的首次公开募股（IPO），RayzeBio是一家放射性药物治疗公司，拥有一项主要资产，即用于治疗胃肠胰腺神经内分泌肿瘤的临床3期开发阶段的锕-225（Ac-225）dotatate。该公司在2023年9月15日在纳斯达克上市时筹集了3.58亿美元，上市后估值接近10亿美元。这是迄今为止年度第二大生物技术IPO，仅次于Acelyrin募集的5.4亿美元，是2023年医疗保健IPO平均规模的约2.9倍。2023年12月26日，RayzeBio与百时美施贵宝签署了最终合并协议，以41亿美元的价格被收购。RayzeBio股价当时溢价134%。一天后，礼来公司宣布以14亿美元的价格收购POINT Biopharma，该价格比POINT Biopharma在2023年10月3日宣布收购前一天的收盘价溢价87%。大型制药公司愿意为放射性制药公司支付高额溢价，进一步表明了该领域日益增长的兴趣。写在最后随着大量投资涌入早期放射性药物公司，作者预计随着这些新技术的成熟，制药公司将继续进行授权和并购活动。此外，随着对个性化医疗的日益重视，诊断加治疗的模式可能会继续受到人们的青睐；实际上，在上文的分析中，治疗诊断在考虑的模式中获得了最大的前期价值。放射性药物在肿瘤学以外的领域的使用可能会吸引更多的公司和风险投资商。由于放射性药物在可视化大脑和其他中央神经系统部分方面的独特能力，神经学在诊断交易中处于领先地位。总体而言，随着交易的继续进行，放射性药物领域充满了期待和期望。参考资料：The radiopharmaceutical renaissance: radiating hope in cancer therapy共建Biomedical创新生态圈！如何加入BiG会员？

放射疗法临床3期

2024-03-07

·同写意

核药：下一个风口上的肿瘤“刺客”

为打造全球ADC/RDC未来产业高地，成都医学城拟于2024年4月18日-19日举办首届未来XDC新药大会！大会以“共创偶联药物产业未来”为主题，由同写意策划，其中设未来核药会议系列论坛，“核药全流程开发（讲习班）、分会六：拥抱核药产业未来、分会七：核药源头创新与前沿技术、分会八：核药上下游产业链论坛”将围绕核药展开全面深入探讨，欢迎报名！二代放射性药物在肿瘤领域的商业成功重新点燃了投资者对该领域的兴趣，相关交易和融资的也应声激增。预计到2032年全球核药市场将达到103亿美金规模，行业增长率高达8.85%。全身性放射性药物作为癌症的治疗方法最初于 1940 年代使用，当时医生利用放射性碘来治疗甲状腺癌。然而，早期放疗缺乏效力以及由于缺乏特异性而产生的副作用，科学家和临床医生一直致力于通过将放射性同位素与靶向部分（如肿瘤特异性小分子、肽或抗体）联系起来来开发更安全、更有效的药物。商业化的抗体靶向放射治疗药物的出现始于本世纪初，2002 年和 2003 年，Zevalin（ibritumomab tiuxetan;现在由 Acrotech Biopharma 销售）和 Bexxar（tositumomab 和 iodine-131 [I-131] tositumomab;由葛兰素史克公司开发）分别被批准用于治疗非霍奇金淋巴瘤。尽管临床疗效优异，但一些关键挑战——包括对专业设施、设备和生产和处理专业知识的需求——限制了他们的商业成功。Zevalin 和 Bexxar 的销量在推出后的十多年一直很低，导致 Zevalin 的所有权多次发生变化，Bexxar 被撤出市场。不同的是，第二代放射性药物Xofigo（镭-223[Ra-223]二氯化物;拜耳，2013 年获批）、Lutathera（镥-177 [Lu-177] dotatate，2018 年批准）和 Pluvicto（镥-177 [Lu-177] vipivotide tetraxetan;诺华，2022年获批），由于采取了一些应对措施，已取得了一定的商业成功。事实上，被批准用于治疗转移性去势抵抗性前列腺癌的Pluvicto已经有望成为重磅炸弹，诺华在2023年全年的销售额达到9.8亿美元。与现有的标准疗法相比，更优的疗效、肿瘤学临床实践的发展、放射肿瘤学家的增多、以及使用具有更高稳定性和安全性的放射性同位素等等新的措施的使用，这些汇聚在一起，使得核药领域焕发了“第二春”。也正是更有效、更安全、更易于使用的具有强大商业潜力的药物的出现激发了投资者对该领域的兴趣，导致了最近一系列的许可合作伙伴关系、并购（M&A）和风险投资（VC）融资。下文总结评估了过去 5 年里放射性药物领域的交易和投资格局，涵盖治疗、诊断和治疗诊断学等。1放射性药物交易过去 5 年中，放射性药物领域共达成了 86 项战略交易，其中大部分是合作/共同开发（n = 26）和基于许可的协议（n = 26）。从2018年到2021年，交易数量相对稳定。然而，在 2022 年，达成的交易数量与 2021 年相比几乎增加了两倍（分别为 n = 25 和 n = 9;图1a）。值得注意的是，在临床前阶段（n = 20）的资产交易数量最多，主要是由具有现有核医学能力和专业知识的公司（如Fusion Pharmaceuticals和Novartis）推动的，这些公司正在寻求扩大其放射性药物管线。许多交易也发生在II期临床药物（n = 18）;这些主要是基于放射性诊断药物的许可和收购交易，用于识别最适合作公司治疗资产的患者（图1a）。图 1 |生物制药赞助的放射性药物领域交易分配：2018-2023年。a，每年按阶段划分的交易数量。b，按适应症、按用途分列的交易数量。数据来源：Cortellis。*至2023年10月3日。该领域活跃的整合者包括全球生物制药公司（如诺华和拜耳）和专门的核制药公司（如Fusion Pharmaceuticals和Curium Pharma），交易活动遍及诊断、治疗和治疗药物。放射性诊断药物在该领域的交易总数中占据了相当大的比例（~41%），其次是治疗诊断学（~32%）和治疗学（~27%;图1b）。虽然肿瘤学在治疗诊断学和治疗学交易领域占据主导地位（分别占交易的93%和100%），但诊断领域交易的最大部分是神经病学（54%），其次是肿瘤学（31%）。在分析的期间内，有 17 笔交易在公告时披露了财务条款（~20%）。在开发和模式的所有阶段，商业前交易的平均潜在总价值为8.34亿美元（前期2.84亿美元，里程碑5.5亿美元）（图2a）。与诊断资产的平均总交易价值（3900万美元;n = 4），治疗诊断学（n = 4）和治疗（n = 9）资产的潜在交易价值要高得多，分别为 7.29 亿美元和 10.26 亿美元。治疗诊断资产的平均前期交易价值是治疗资产的~2倍，这可能归因于前者的临床和监管风险较低。当按资产成熟度考虑交易价值时，随着技术在临床上的进展，临床阶段的资产价值不断增加，但与早期临床资产相比，发现阶段的交易实现了更高的总交易价值（图2b）。在发现阶段达成的交易的大部分（97%）价值在于里程碑付款，这反映了这些基于合作的交易在放射性药物疗法的发现、开发和商业化方面的高风险、高回报性质。图 2 |生物制药赞助的放射性药物领域的交易价值：2018-2023年*。a，按方式分列的具有披露条款的交易价值。b，按阶段划分的具有披露条款的交易价值。数据来源：Cortellis。*至2023年10月3日。商业阶段的交易主要是对拥有被FDA批准上市产品公司的收购。值得注意的是，诺华在2018年支付了39亿美元的预付款收购了Advanced Accelerator Applications，随后FDA批准了其神经内分泌肿瘤（NET）诊断Netspot（镓[ga-68]dotatate试剂盒），几乎同时FDA批准了治疗药物Lutathera。2公司融资 2018 年以来，放射性药物领域的融资数量（n = 54）一直在稳步增加，主要集中在癌症适应症上（n = 45;图 3）。治疗学是最活跃的融资方式（50%），其次是治疗（34%）和诊断（16%），大部分融资发生在早期，分别在A轮（56%）和B轮（32%）。随着兴趣和临床开发的不断提高，融资水平也在上升;2023 年前三季度 9 次融资的平均融资额为 5100 万美元，是 2018 年全年的 ~2 倍，4 次融资的 2600 万美元（图 3）。图 3 |放射性药物领域风险资本支持的私人融资：2018-2023年*。融资范围从A轮到D轮，数据来源：Pitchbook。*至2023年10月3日。3上市公司业绩虽然对放射性药物的热情导致交易增加，但自 2023 年初起在美国主要交易所（纽约证券交易所或纳斯达克）上市的五家放射性药物公司——Fusion Pharmaceuticals、Lantheus Medical Imaging、POINT Biopharma、Perspective Therapeutics 和 Actinium Pharmaceuticals——的表现喜忧参半。从年初到 2023 年 10 月 3 日，他们的表现从 POINT Biopharma 的股价上涨 71% 到 Actinium Pharmaceuticals 的股价下跌 43% 不等。五家公司中位数公司Perspective Therapeutics的股价上涨了11%，远高于纳斯达克生物技术指数，纳斯达克生物技术指数在同一时间段内的回报率为-7%。公共放射性制药公司平均表现积极的一个可能的解释是，围绕私人市场模式蔓延到公开市场的兴奋。强化这一理论的是RayzeBio的首次公开募股（IPO），这是一家放射性药物治疗公司，其主要资产是actinium-225（Ac-225）dotatate，处于治疗胃肠胰神经内分泌瘤的III期开发阶段。该公司于 2023 年 9 月 15 日在纳斯达克上市时筹集了 3.58 亿美元，上市后的估值接近 10 亿美元。这是今年迄今为止第二大生物技术 IPO，仅次于 Acelyrin 的 5.4 亿美元融资，是 2023 年医疗保健 IPO 平均规模的 ~2.9 倍。截至 2023 年底，两家上市放射性药物公司已达成收购协议，另外两家大型制药公司加入了诺华和拜耳的行列。2023 年 12 月 26 日，RayzeBio 与百时美施贵宝达成最终合并协议，以 41 亿美元收购，比 RayzeBio 当时的股价溢价 134%。一天后，礼来宣布以 14 亿美元完成对 POINT Biopharma 的收购，比 POINT 在 2023 年 10 月 3 日宣布收购前一天的收盘价溢价 87%。大型制药公司愿意为放射性药物公司支付高额溢价，这进一步表明了人们对该领域的兴趣日益浓厚。— 总结 — 随着大量投资涌入早期放射性药物公司，预计随着这些新技术的成熟，制药公司将继续其许可和并购活动。此外，随着对个性化医疗的日益重视，治疗诊断学可能会继续引起人们的浓厚兴趣；放射性药物在肿瘤学以外的领域的使用可能会带来更多的公司和风险投资公司。事实上，神经病学在诊断交易方面处于领先地位，因为放射性药物具有可视化大脑和中枢神经系统其他部分的独特能力。总体而言，随着交易的继续，放射性药物领域充满了期待和高期望。近期直播推荐:

抗体药物偶联物放射疗法并购

2023-10-09

·PRNewswire

Global Radiopharmaceuticals Strategic Analysis Report 2023-2030: Shaping the Future of Healthcare - Precision Medicine Powered by Radiopharmaceuticals

DUBLIN, Oct. 9, 2023 /PRNewswire/ -- The "Radiopharmaceuticals - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Radiopharmaceuticals Market to Reach $14.3 Billion by 2030 The global market for Radiopharmaceuticals estimated at US$6.3 Billion in the year 2022, is projected to reach a revised size of US$14.3 Billion by 2030, growing at a CAGR of 10.8% over the analysis period 2022-2030. This analysis provides insights into the historical performance, current status, and future projections for radioisotopes across various applications, including oncology, cardiology, endocrine tumors, neurology, and more. The report offers a 14-year perspective on sales percentages for 2016, 2023, and 2030, delivering valuable insights into market trends and dynamics. Within the report, the SPECT Radioisotopes segment is expected to achieve a remarkable 10.4% CAGR, reaching a market value of US$6.2 billion by the end of the analysis period. Additionally, the Pet Radioisotopes segment is projected to grow at a strong 9.8% CAGR over the next eight years. The U.S. market is estimated at US$3.1 billion in 2022, while China, as the world's second-largest economy, is forecasted to attain a market size of approximately US$1.2 billion by 2030, with an impressive CAGR of 13.9% during the 2022-2030 analysis period. The global SPECT and PET radioisotopes market is comprehensively evaluated in this report, focusing on annual sales data from 2016 to 2030 and encompassing various geographic regions, including the USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. Furthermore, the report provides detailed insights into the competitive landscape, including prominent names like Bayer HealthCare Pharmaceuticals, GE Healthcare, and Actinium Pharmaceuticals, Inc., to enhance your strategic planning initiatives. What`s New? Special discussions on the global economic climate and market sentiment Coverage on global competitiveness and key competitor percentage market shares Market presence analysis across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to digital archives and trademarked research platform Complimentary updates for one year Access to curated YouTube video transcripts of market sentiments shared by CEOs, domain experts and market influencers via interviews, podcasts, press statements and event keynotes MARKET OVERVIEW Radiopharmaceuticals: A Prelude Mechanism of Action Global Economic Update From Pandemic to War & Inflation: "Subdued Outlook for 2023 Despite Signs of Easing Inflationary Conditions" Here's How Inflationary Pressures Affect the Economy Although Past Peak in 2023, Efforts to Solve the Inflation Puzzle Should Continue Slower Than Anticipated Decline Makes Inflation a Stickier Than Expected Problem to Solve in 2023: Global Inflation Rates (In %) for the Years 2019 Through 2024 Global Economy Faces a Tough Climb Towards Recovery Made Rockier by the War, Anti-Inflation Fiscal Policies & Slower Than Desirable Easing of Inflationary Pressures: World Economic Growth Projections (Real GDP, Annual % Change) for the Years 2020 Through 2024 Pandemic-Led Disruptions Affect Radiopharmaceuticals Supply Imaging Screening Volume % Change 1H 2019 Vs 1H 2020 in US Hospitals Hospitals Struggle as Distribution Bottlenecks Affect Supply of Medical Radioisotopes Nuclear Medicine Services Back to Normal Pandemic Presents Generational Opportunity Global Market Outlook Key Market Drivers Market Restraints Recognition of Intrinsic Cost Benefits: Critical to Market Acceptance Classification of Radiopharmaceuticals Diagnostic Radiopharmaceuticals: The Dominant Segment Positron Emission Tomography (PET) Single Photon Emission Computed Tomography (SPECT) Therapeutic Radiopharmaceuticals Supply Shortages Remain a Challenge to Market Growth A Glimpse at Mo-99 Processors Worldwide Nuclear Research Reactor Irradiators Worldwide: A Snapshot Competition Radiopharmaceuticals - Global Key Competitors Percentage Market Share in 2023 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E) Recent Market Activity MARKET TRENDS & DRIVERS Emergence of Radiotheranostics: Dual-Functioning Radiopharmaceuticals Radiopharmaceuticals Become Promising for Cancer Theranostics Changing Role of Radiopharmaceuticals in Diagnostic and Therapeutic Applications Notable Clinical Applications of Radiopharmaceuticals in Nuclear Medicine Advent of New Radiopharmaceuticals Widen Scope Startups Develop Unique Radiopharmaceutical Solutions Potential Role of Carbon Dots in Imaging and Theranostics Nano Radiopharmaceuticals: Promising Role in Therapeutic and Imaging Applications Current Major Focus Areas in Radiopharmaceutical Research R&D Efforts in the Radiopharmaceuticals Market Researchers Develop New Nanoparticles to Improve Radiopharmaceutical Efficiency Oncoinvent and NPL Develop Unique Method to Measure & Deliver Dosages in Radiotherapy Researchers Develop S-Value Database for Simplifying Complexity in Tumor Dosimetry Key Impediments in Academic Research of Radiopharmaceuticals Industry Gears up for Innovative Radiopharmaceuticals with Therapeutic Benefits Role of Radiopharmaceuticals as Diagnostic Technology Promising Molecular Imaging Technology Advancements for SPECT and PET PET Eclipses SPECT in Cardiovascular Imaging Worldwide Installed Base of Nuclear Imaging Equipment by Modality, PET Vs SPECT: 2023E Cardiac Amyloidosis Visualization: A Potential Application for PET Innovative Radiopharmaceuticals to Boost Cardiac Applications Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others Global Annual Medical Cost of Cardiovascular Diseases in US$ Billion (2010-2030) Radiopharmaceuticals: Direct and Targeted Approach for Cancer Treatment Increased Use of Radiopharmaceuticals Across Oncology to Drive Market Growth Rising Cancer Incidence Worldwide Spurs Demand Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 Global Number of New Cancer Cases and Cancer-related Deaths by Cancer Site for 2020 Number of New Cancer Cases and Deaths (in Million) by Region for 2020 Intra-Operative Lymphatic Mapping (ILM) Creates New Opportunities for Radiopharmaceuticals in Cancer Detection Growing Prominence of Therapeutic Radiopharmaceuticals for Cancer Care Radiopharmaceuticals Expand Horizons for Cancer Treatment Arena Radiopharmaceuticals as Potential Silver Bullet to Target & Treat Prostate Cancer Challenges with Radiopharmaceuticals for Cancer Rise in Incidence of Neurological Disorders to Drive Growth Application of PET in Drug Development to Expand Opportunities Personalized Medicine Drives Nuclear Medicine Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population Global Personalized Medicines Market (in US$ Billion) for the Years 2022, 2025 and 2028 Need for Guidance for Manufacture of Investigational Radiopharmaceuticals for Clinical Trials Technetium-99m to Hold Immense Potential for Use in Diagnostic Nuclear Medicine in the Future Shortage of 99Mo and 99mTc to Adversely Impact Provider Care and Patient Access Novel Production Method Promises to End Problems of 99mTc Shortages New Approach for Production of Clinical Radiopharmaceuticals Gallium-68-labeled Radiopharmaceuticals: Production & Administering Challenges Radiopharmaceuticals for COVID-19: Role in Diagnosis, Prognosis, and Therapeutic Uses Arti?cial Intelligence: A Promising Tool in Radiotherapy and Radiopharmaceuticals Nuclear Medicine & AI to Power the Future of Precision Medicine Aging Global Population: A Vital Demography Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Rise in Healthcare Expenditure to Drive Growth World Healthcare Expenditure (In US$ Trillion) for the Years for 2017, 2019, 2021 & 2023 Relevant Aspects of Radiopharmaceutical Production Regulatory Regime Governing Production and Use of Radiopharmaceuticals The Facilitating Innovative Nuclear Diagnostics (FIND) Act, 2021 Challenges Facing Nuclear Medicine Industry FOCUS ON SELECT PLAYERS (Total 141 Featured) Actinium Pharmaceuticals, Inc. Advanced Accelerator Applications Alliance Medical Ltd. Bayer HealthCare Pharmaceuticals Bracco Diagnostics, Inc. Cardinal Health, Inc. Curium US LLC GE Healthcare IBA Radiopharma Solutions Jubilant DraxImage Inc. Lantheus Medical Imaging Inc. Medi-Radiopharma Ltd. Nordion Inc. Radiopharm Theranostics Ltd. Siemens Healthcare GmbH For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

放射疗法

100 项与 Lantheus Medical Imaging, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Lantheus Medical Imaging, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2024年11月05日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床1期

临床2期

临床3期

批准上市

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

全氟丙烷脂质微球	造影剂更多	批准上市
Sodium Pertechnetate (99mTc)	甲状腺疾病更多	批准上市
锝[99mTc]比西酯	中枢神经系统创伤更多	批准上市
Technetium Tc 99m trofolastat ( PSMA )	前列腺癌更多	临床3期
CarThera	胶质母细胞瘤更多	临床2期